Dimorphic Effects of Transforming Growth Factor-β Signaling during Aortic Aneurysm Progression in Mice Suggest a Combinatorial Therapy for Marfan Syndrome

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 4, 2015, Pages 911-917

  Cook, Jason R ^a   Clayton, Nicholas P ^b   Carta, Luca ^a   Galatioto, Josephine ^a   Chiu, Emily ^a   Smaldone, Silvia ^a   Nelson, Carol A ^b,c   Cheng, Seng H ^b   Wentworth, Bruce M ^b   Ramirez, Francesco ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b SANOFI   (France)

^c Translational Medicine Consulting   (United States)

Author keywords

aortic aneurysm; losartan; Marfan syndrome; receptor, angiotensin, type 1; transforming growth factor

Indexed keywords

LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1D11; PLACEBO; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; FIBRILLIN; MAPK1 PROTEIN, MOUSE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUTRALIZING ANTIBODY; SMAD2 PROTEIN; SMAD2 PROTEIN, MOUSE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMICAL ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; MARFAN SYNDROME; MOUSE; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SURVIVAL; THORACIC AORTA ANEURYSM; TREATMENT DURATION; 129 MOUSE; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTIC ANEURYSM, THORACIC; AORTIC RUPTURE; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MUTANT MOUSE STRAIN; MUTATION; PATHOLOGY; PHOSPHORYLATION; THORACIC AORTA; TIME FACTOR;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIBODIES, NEUTRALIZING; AORTA, THORACIC; AORTIC ANEURYSM, THORACIC; AORTIC RUPTURE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; LOSARTAN; MARFAN SYNDROME; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MICROFILAMENT PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUTATION; PHOSPHORYLATION; RECEPTOR, ANGIOTENSIN, TYPE 1; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84933677647     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.305150     Document Type: Article

References (25)

1. Lindsay ME, Dietz HC. Lessons on the pathogenesis of aneurysm from heritable conditions. Nature. 2011;473:308-316. doi: 10.1038/ nature10145.
2. Milewicz DM, Guo DC, Tran-Fadulu V, Lafont AL, Papke CL, Inamoto S, Kwartler CS, Pannu H. Genetic basis of thoracic aortic aneurysms and dissections: focus on smooth muscle cell contractile dysfunction. Annu Rev Genomics Hum Genet. 2008;9:283-302. doi: 10.1146/annurev. genom.8.080706.092303.
3. Chen X, Lu H, Rateri DL, Cassis LA, Daugherty A. Conundrum of angiotensin II and TGF-β interactions in aortic aneurysms. Curr. Opin. Pharmacol. 2013;13:1-6.
4. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312:117-121. doi: 10.1126/science.1124287.
5. Dai J, Losy F, Guinault AM, Pages C, Anegon I, Desgranges P, Becquemin JP, Allaire E. Overexpression of transforming growth factorbeta1 stabilizes already-formed aortic aneurysms: A first approach to induction of functional healing by endovascular gene therapy. Circulation. 2005;112:1008-1015. doi: 10.1161/CIRCULATIONAHA.104.523357.
6. Wang Y, Ait-Oufella H, Herbin O, Bonnin P, Ramkhelawon B, Taleb S, Huang J, Offenstadt G, Combadière C, Rénia L, Johnson JL, Tharaux PL, Tedgui A, Mallat Z. TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J Clin Invest. 2010;120:422-432. doi: 10.1172/JCI38136.
7. Judge DP, Biery NJ, Keene DR, Geubtner J, Myers L, Huso DL, Sakai LY, Dietz HC. Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. J Clin Invest. 2004;114:172-181. doi: 10.1172/JCI20641.
8. Chung AW, Yang HH, van Breemen C. Imbalanced synthesis of cyclooxygenase-derived thromboxane A2 and prostacyclin compromises vasomotor function of the thoracic aorta in Marfan syndrome. Br J Pharmacol. 2007;152:305-312. doi: 10.1038/sj.bjp.0707391.
9. Pereira L, Lee SY, Gayraud B, Andrikopoulos K, Shapiro SD, Bunton T, Biery NJ, Dietz HC, Sakai LY, Ramirez F. Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1. Proc Natl Acad Sci U S A. 1999;96:3819-3823.
10. Holm TM, Habashi JP, Doyle JJ, et al. Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science. 2011;332:358-361. doi: 10.1126/science.1192149.
11. Nistala H, Lee-Arteaga S, Carta L, Cook JR, Smaldone S, Siciliano G, Rifkin AN, Dietz HC, Rifkin DB, Ramirez F. Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome. Hum Mol Genet. 2010;19:4790-4798. doi: 10.1093/hmg/ddq409.
12. Xiong W, Meisinger T, Knispel R, Worth JM, Baxter BT. MMP-2 regulates Erk1/2 phosphorylation and aortic dilatation in Marfan syndrome. Circ Res. 2012;110:e92-e101. doi: 10.1161/CIRCRESAHA.112. 268268.
13. Li W, Li Q, Jiao Y, Qin L, Ali R, Zhou J, Ferruzzi J, Kim RW, Geirsson A, Dietz HC, Offermanns S, Humphrey JD, Tellides G. Tgfbr2 disruption in postnatal smooth muscle impairs aortic wall homeostasis. J Clin Invest. 2014;124:755-767. doi: 10.1172/JCI69942.
14. Carta L, Smaldone S, Zilberberg L, Loch D, Dietz HC, Rifkin DB, Ramirez F. p38 MAPK is an early determinant of promiscuous Smad2/3 signaling in the aortas of fibrillin-1 (Fbn1)-null mice. J Biol Chem. 2009;284:5630-5636. doi: 10.1074/jbc.M806962200.
15. Matt P, Schoenhoff F, Habashi J, Holm T, Van Erp C, Loch D, Carlson OD, Griswold BF, Fu Q, De Backer J, Loeys B, Huso DL, McDonnell NB, Van Eyk JE, Dietz HC; GenTAC Consortium. Circulating transforming growth factor-beta in Marfan syndrome. Circulation. 2009;120:526-532. doi: 10.1161/CIRCULATIONAHA.108.841981.
16. Nelson CA, Hunter RB, Quigley LA, Girgenrath S, Weber WD, McCullough JA, Dinardo CJ, Keefe KA, Ceci L, Clayton NP, McVie-Wylie A, Cheng SH, Leonard JP, Wentworth BM. Inhibiting TGF-β activity improves respiratory function in mdx mice. Am J Pathol. 2011;178:2611-2621. doi: 10.1016/j.ajpath.2011.02.024.
17. Liu S, Song W, Boulanger JH, et al. Role of TGF-β in a mouse model of high turnover renal osteodystrophy. J Bone Miner Res. 2014;29:1141-1157. doi: 10.1002/jbmr.2120.
18. Edwards JR, Nyman JS, Lwin ST, Moore MM, Esparza J, O'Quinn EC, Hart AJ, Biswas S, Patil CA, Lonning S, Mahadevan-Jansen A, Mundy GR. Inhibition of TGF-β signaling by 1D11 antibody treatment increases bone mass and quality in vivo. J Bone Miner Res. 2010;25:2419-2426. doi: 10.1002/jbmr.139.
19. Biswas S, Nyman JS, Alvarez J, Chakrabarti A, Ayres A, Sterling J, Edwards J, Rana T, Johnson R, Perrien DS, Lonning S, Shyr Y, Matrisian LM, Mundy GR. Anti-transforming growth factor ß antibody treatment rescues bone loss and prevents breast cancer metastasis to bone. PLoS One. 2011;6:e27090. doi: 10.1371/journal.pone.0027090.
20. Grafe I, Yang T, Alexander S, et al. Excessive transforming growth factor-β signaling is a common mechanism in osteogenesis imperfecta. Nat Med. 2014;20:670-675. doi: 10.1038/nm.3544.
21. Wagenseil JE, Mecham RP. Vascular extracellular matrix and arterial mechanics. Physiol Rev. 2009;89:957-989. doi: 10.1152/ physrev.00041.2008.
22. Humphrey JD, Milewicz DM, Tellides G, Schwartz MA. Cell biology. Dysfunctional mechanosensing in aneurysms. Science. 2014;344:477-479. doi: 10.1126/science.1253026.
23. Groenink M, den Hartog AW, Franken R, Radonic T, de Waard V, Timmermans J, Scholte AJ, van den Berg MP, Spijkerboer AM, Marquering HA, Zwinderman AH, Mulder BJ. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: A randomized controlled trial. Eur Heart J. 2013;34:3491-3500. doi: 10.1093/eurheartj/eht334.
24. Lacro RV, Dietz HC, Sleeper LA, et al; Pediatric Heart Network Investigators. Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med. 2014;371:2061-2071. doi: 10.1056/ NEJMoa1404731.
25. Massagué J. TGFβ signaling in context. Nat. Rev. Mol. Cell Biol. 2012;13:616-630.